L
Laura Heenan
Researcher at Population Health Research Institute
Publications - 13
Citations - 353
Laura Heenan is an academic researcher from Population Health Research Institute. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 3, co-authored 4 publications receiving 54 citations. Previous affiliations of Laura Heenan include University of Washington.
Papers
More filters
Journal ArticleDOI
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Hertzel C. Gerstein,Naveed Sattar,Julio Rosenstock,Chinthanie Ramasundarahettige,Richard Pratley,Renato D. Lopes,Carolyn S.P. Lam,Nardev S. Khurmi,Laura Heenan,Stefano Del Prato,Leanne Dyal,Kelley R. Branch +11 more
TL;DR: In this article, four glucagon-like peptide-1 (GLP-1) receptor agonists were shown to reduce the risk of adverse cardiovascular events among per capita patients.
Journal ArticleDOI
Household and personal air pollution exposure measurements from 120 communities in eight countries: results from the PURE-AIR study.
Matthew Shupler,Matthew Shupler,Perry Hystad,Aaron Birch,Daniel Miller-Lionberg,Matthew Jeronimo,Raphael E. Arku,Yen Li Chu,Maha Mushtaha,Laura Heenan,Sumathy Rangarajan,Pamela Seron,Fernando Lanas,Fairuz Cazor,Patricio Lopez-Jaramillo,Paul A. Camacho,Maritza Pérez,Karen Yeates,Nicola West,Tatenda Ncube,Brian Ncube,Jephat Chifamba,Rita Yusuf,Afreen Zaman Khan,Bo Hu,Xiaoyun Liu,Li Wei,Lap Ah Tse,Deepa Mohan,Parthiban Kumar,Rajeev Gupta,Indu Mohan,KG Jayachitra,Prem Mony,Kamala Rammohan,Sanjeev Nair,P V M Lakshmi,Vivek Sagar,R Khawaja,Romaina Iqbal,Khawar Kazmi,Salim Yusuf,Michael Brauer,Pure-Air study +43 more
TL;DR: Average kitchen and personal PM2·5 measurements for all primary fuel types exceeded WHO’s Interim Target-1 (35 μg/m3 annual average), highlighting the need for comprehensive pollution mitigation strategies.
Journal ArticleDOI
Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures: The UNIVERSAL Randomized Clinical Trial.
Sanjit S. Jolly,Sulaiman Alrashidi,Marc-André d’Entremont,Omar Alansari,Bradley D. Brochu,Laura Heenan,Elizabeth Skuriat,Jessica Tyrwhitt,Michael D. Raco,Michael Tsang,Nicholas Valettas,James L. Velianou,Tej Sheth,Matthew Sibbald,Shamir R. Mehta,Natalia Pinilla-Echeverri,Jon-David Schwalm,Madhu K. Natarajan,Andrew Kelly,E. Y. Akl,Sarah Tawadros,Mercedes Camargo,W. Faidi,John D. Bauer,Rachel Moxham,James Nkurunziza,Gustavo Dutra,José Luis Winter +27 more
TL;DR: In this randomized clinical trial, use of ultrasonography for femoral access did not reduce bleeding or vascular complications, however, ultraasonography did reduce the risk of venipuncture and number of attempts.
Journal ArticleDOI
Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.
Hertzel C. Gerstein,Hertzel C. Gerstein,Kelley R. Branch,Laura Heenan,Stefano Del Prato,Nardev S. Khurmi,Carolyn S.P. Lam,Richard E. Pratley,Julio Rosenstock,Naveed Sattar +9 more
TL;DR: The effect of the weekly exendin‐based glucagon‐like peptide‐1 receptor agonist efpeglenatide on cardiovascular outcomes in high‐risk patients with type 2 diabetes with and without chronic kidney disease (CKD) is unknown.
Journal ArticleDOI
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
John W. Eikelboom,Sanjit S. Jolly,Emilie P. Belley-Côté,Richard P. Whitlock,Sumathy Rangarajan,Lizhen Xu,Laura Heenan,Shrikant I. Bangdiwala,M. Luz Diaz,R. Diaz,Afzalhussein Yusufali,Sanjib Kumar Sharma,Wadea Tarhuni,Mohamed Hassany,Alvaro Avezum,William Harper,Sean Wasserman,Aysha Almas,O. M. Drapkina,Camilo Felix,Renato D. Lopes,Otavio Berwanger,Patricio Lopez-Jaramillo,Sonia S. Anand,Jackie Bosch,Shurjeel Choudhri,Michael E. Farkouh,Mark Loeb,Salim Yusuf +28 more
TL;DR: Results were consistent in subgroups defined by vaccination status, disease severity at baseline, and timing of randomisation in relation to onset of symptoms, as well as in patients assigned to colchicine or control and the combination of rivaroxaban and aspirin.